Travere Therapeutics' Profit After Tax rose 146.90% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.5 million, marking a year-over-year increase of 74.81%. This contributed to the annual value of -$321.5 million for FY2024, which is 14.56% up from last year.
Latest data reveals that Travere Therapeutics reported Profit After Tax of $25.7 million as of Q3 2025, which was up 301.54% from -$12.8 million recorded in Q2 2025.
Over the past 5 years, Travere Therapeutics' Profit After Tax peaked at $150.7 million during Q3 2023, and registered a low of -$136.1 million during Q1 2024.
Its 3-year average for Profit After Tax is -$44.3 million, with a median of -$60.3 million in 2024.
In the last 5 years, Travere Therapeutics' Profit After Tax tumbled by 6,766.71% in 2021 and then spiked by 279.31% in 2023.
Quarterly analysis of 5 years shows Travere Therapeutics' Profit After Tax stood at -$88.8 million in 2021, then rose by 3.53% to -$85.6 million in 2022, then declined by 5.30% to -$90.2 million in 2023, then skyrocketed by 33.17% to -$60.3 million in 2024, then soared by 146.90% to $25.7 million in 2025.
Its last three reported values are $25.7 million in Q3 2025, -$12.8 million for Q2 2025, and -$41.2 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value